GlassScriptPhysician profile
Andrew J Klein
NPI 1366482424
$11,691.25
in general payments reported to CMS, 2019-2025
27 companies · $2,857 in 2025
The $2,857 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,307 · 2020: $244 · 2021: $1,732 · 2022: $1,277 · 2023: $1,846 · 2024: $1,428 · 2025: $2,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,493 · Travel and Lodging: $1,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,492.83 |
| Travel and Lodging | $1,638.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $2,256.99 | 2019-2022 | |
| Endovascular Engineering INC. | $1,920.44 | 2024-2025 | Helo Thrombectomy System |
| Boston Scientific Corporation | $1,741.75 | 2019-2025 | Ekosonic, Varithena Administration Pack, General - Vascular Access |
| Datascope Corp. | $1,200.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $949.67 | 2020-2025 | |
| Angiodynamics, INC. | $669.34 | 2022-2025 | Alphavac |
| Janssen Pharmaceuticals, INC | $666.52 | 2019-2024 | Xarelto |
| Medtronic, INC. | $488.99 | 2021-2025 | Onyx Frontier, Hawkone, Corevalve Evolut R |
| Abiomed | $404.56 | 2019-2025 | |
| Shockwave Medical, INC | $328.78 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Edwards Lifesciences Corporation | $160.02 | 2022-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $149.44 | 2019-2024 | Lifevest |
| Chiesi USA, INC. | $133.30 | 2025 | Kengreal |
| Ekos Corporation | $112.41 | 2019 | |
| Amgen INC. | $95.95 | 2020-2023 | Repatha |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $92.85 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $78.71 | 2024-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $48.89 | 2024 | Mitraclip, Esprit |
| Astrazeneca Pharmaceuticals LP | $37.87 | 2023-2024 | Andexxa, Wainua |
| Kestra Medical Technology Services, INC. | $35.01 | 2023-2024 | Assure Wcd |
| Bridgebio Pharma, INC. | $32.08 | 2025 | Attruby |
| Pfizer INC. | $30.24 | 2021 | |
| Biotronik INC. | $29.70 | 2022 | |
| Asahi Intecc USA, INC. | $14.02 | 2024 | Peripheral Vascular |
| Reflow Medical INC | $13.72 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.